Literature DB >> 15665615

The immunoreactivity of radiolabeled antibodies--its impact on tumor targeting and strategies for preservation.

Raymond Reilly.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15665615     DOI： 10.1089/cbr.2004.19.669

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN： 1084-9785            Impact factor:   3.099


× No keyword cloud information.
  3 in total

Review 1.  B7-H3-targeted Radioimmunotherapy of Human Cancer.

Authors:  Benjamin B Kasten; Soldano Ferrone; Kurt R Zinn; Donald J Buchsbaum
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

2.  Radioimmunotheranostic Pair Based on the Anti-HER2 Monoclonal Antibody: Influence of Chelating Agents and Radionuclides on Biological Properties.

Authors:  Ana Cláudia Camargo Miranda; Sofia Nascimento Dos Santos; Leonardo Lima Fuscaldi; Luiza Mascarenhas Balieiro; Maria Helena Bellini; Maria Inês Calil Cury Guimarães; Elaine Bortoleti de Araújo
Journal:  Pharmaceutics       Date:  2021-06-27       Impact factor: 6.321

3.  123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1/Cip-1).

Authors:  Meiduo Hu; Paul Chen; Judy Wang; Deborah A Scollard; Katherine A Vallis; Raymond M Reilly
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-09-26       Impact factor: 9.236
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.